2/22 ANRis CEO Yoshihiko Shiono to speak at JHVS symposiumした

CEO of ANRis, Yoshihiko Shiono had a pitch at the “JHVS Symposium for Medical Ventures and Academia” held on February 22, 2025.

2/17 ANRis has been selected for the second term of the 2024 “IP Acceleration program for Startups　(IPAS).”

ANRis has been selected for the second term of the 2024 “IP Acceleration program for Startups　(IPAS) by National Center for Industrial Property Information and Training (INPIT).

7/9 ANRis won the KRP Award at HVC KYOYO 2024

At the HVC KYOTO 2024 Demo Day, held on July 8-9 at Kyoto Research Park (KRP), our CTO, Kumiko Ui-Tei, took the stage for the final pitch and was honored with the KRP Award.

7/8 We received an investment from QB Capital, through the QB II Investment Limited Partnership, which is jointly managed by QB Capital,LLC and NCB Venture Capital Co.,Ltd. 

With the investment from the QB II Investment Limited Partnership, we will accelerate the development of pharmaceuticals based on our SNPD-siRNA technology. 

https://qbc.co.jp/2024/07/08/news_240708/

https://ncbvc.co.jp/news/id/54

6/26~28 Sponsored the 25th Annual Meeting of the RNA Society of Japan.

ANRis is pleased to sponsor the 25th Annual Meeting of the RNA Society of Japan, chaired by our CTO, Kumiko Ui-Tei.
Website:https://www.rnaj.org/rna2024

6/7 Selected as one of the 25 startups for the “HVC KYOTO 2024: Startups Taking on Global Markets” program.

We have been selected as one of the 25 startups for “HVC KYOTO 2024: Startups Taking on Global Markets.”
Website:https://www.krp.co.jp/hvckyoto/detail/4446.html

2/8 Featured in Nikkei Biotechnology.

ANRis was featured in Nikkei Biotechnology under the headline: “ANRis Developing siRNA Therapeutics Targeting Single Nucleotide Mutations for Cancer and Genetic Diseases.”

11/28 Featured in Nikkan Kogyo Shimbun.

ANRis was featured in Nikkan Kogyo Shimbun under the headline: “University of Tokyo Startup Develops New Drugs Using Small RNA – Raises 200 Million Yen from Waseda University Ventures.”

https://www.nikkan.co.jp/articles/view/00693962

11/28 Raised approximately 200 million yen from WASEDA University Ventures

We have received a 200 million yen seed investment from WASEDA University Ventures. With this funding, we will strengthen our preparations and infrastructure for preclinical trials.

9/27 Establishment of ANRis, Inc.

Established ANRis Inc. on September 27, 2023.